BeOne Medicines (NASDAQ:ONC) Director Corazon (Corsee) Sanders Sells 212 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Corazon (Corsee) Sanders sold 212 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $309.59, for a total transaction of $65,633.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Down 0.8%

ONC opened at $300.01 on Thursday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a 50 day moving average price of $301.85 and a 200-day moving average price of $321.12. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $235.57 and a twelve month high of $385.22. The stock has a market capitalization of $32.92 billion, a price-to-earnings ratio of 67.12 and a beta of 0.50.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion during the quarter. Equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Mariner LLC boosted its position in shares of BeOne Medicines by 3.8% during the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after acquiring an additional 32 shares during the last quarter. Signaturefd LLC boosted its position in shares of BeOne Medicines by 10.7% during the fourth quarter. Signaturefd LLC now owns 340 shares of the company’s stock worth $103,000 after acquiring an additional 33 shares during the last quarter. Farther Finance Advisors LLC lifted its position in BeOne Medicines by 21.8% during the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after purchasing an additional 39 shares during the last quarter. CWM LLC lifted its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in BeOne Medicines by 4.1% during the third quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock valued at $436,000 after purchasing an additional 50 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ONC. Barclays boosted their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Wolfe Research began coverage on shares of BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 target price for the company. Morgan Stanley restated an “overweight” rating and set a $395.00 target price on shares of BeOne Medicines in a research report on Thursday, May 7th. Finally, Truist Financial restated a “buy” rating and set a $413.00 target price (up from $411.00) on shares of BeOne Medicines in a research report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $389.15.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.